Page 18 - பீட்டர் மக்காலம் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging

SUO 2020: The Role of Prostate-Specific Membrane Antigen (PSMA) Scanning in Prostate Cancer (Up)Staging (UroToday.com) At the 2020 virtual Society of Urologic Oncology s (SUO) prostate cancer session, Dr. Declan Murphy discussed the role of prostate-specific membrane antigen (PSMA) scanning in prostate cancer staging. Dr. Declan Murphy states that PSMA PET/CT is an obvious challenger to conventional imaging. Because there was a lot of retrospective data (particularly in Australia) with PSMA PET-CT, Dr. Murphy and colleagues set out to assess prospectively the use of PSMA PET-CT among patients with high-risk prostate cancer before curative-intent surgery or radiotherapy – the proPSMA study.

United statesZachary klaassenDeclan murphyPeter maccallum cancer centreSociety of urologic oncology annual meetingSociety of urologic oncologyAugusta university medical college of georgiaOutcomes researchGeorgia cancer centerAustralian prostate cancer research centreUrologic oncologyRoyal melbourne hospitalAustralian prostate cancer researchAssistant professorMedical collegeUrologic oncology annual meeting

New theranostic approach reduces tumor volume and increases survival in NET study

E-Mail IMAGE: Representative maximum intensity projection PET/CT images of AR42J tumor-bearing female Balb/c nude mice following injection of 64Cu-CuSarTATE (3 MBq, 0.24 nmol of peptide) at 1 and 4 hours post injection.. view more Credit: Images created by associate professor Carleen Cullinane (Peter MaCallum Cancer Centre). Reston, Virginia A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated

United statesSouth walesSouth australiaPauls donnellyMatthewj harrisKevin kuanRebecca maxeySusan jacksonPeterd roseltDavid binnsRodneyj hicksCharmainem jeffreyCarleen cullinaneJournal of nuclear medicineSir peter maccallum department of oncologyClarity pharmaceuticals ltd

Cutting-Edge Technology Tackles Brain Tumours

VIC Premier Victorian patients with brain tumours and cranial disorders will have a greater chance of survival and improved quality of life thanks to Victoria’s first ever gamma knife. Minister for Health Martin Foley today unveiled the $8 million gamma knife at the Peter MacCallum Cancer Centre. The equipment is funded by the Andrews Labor Government and donors to the Peter MacCallum Cancer Foundation. The world-leading intra-cranial stereotactic radiosurgery and radiotherapy machine is only the third in Australia. It delivers high-intensity cobalt radiation therapy as a non-invasive way to treat lesions inside the skull. The machine uses gamma rays to deliver a precise dose of radiation to the target in the brain to kill cancer cells and shrink tumours, while avoiding damaging healthy brain tissue.

Peter macPeter maccallum cancer centrePeter maccallum cancer foundationHealth martin foleyPeter maccallum cancerAndrews labor governmentHealth martinபீட்டர் மேக்பீட்டர் மக்காலம் புற்றுநோய் மையம்பீட்டர் மக்காலம் புற்றுநோய் அடித்தளம்ஆரோக்கியம் மார்டின் ஃபோலீபீட்டர் மக்காலம் புற்றுநோய்ஆண்ட்ரூஸ் தொழிலாளர் அரசுஆரோக்கியம் மார்டின்

New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study

Date Time New Theranostic Approach Reduces Tumor Volume and Increases Survival in Neuroendocrine Tumor Study Reston, Virginia-A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival. According to new research published in the December issue of The Journal of Nuclear Medicine, the imaging agent 64Cu-CuSarTate produced high-quality positron emission tomography (PET) images in a mouse model of neuroendocrine tumors, while its therapeutic counterpart, 67Cu-CuSarTate, was highly effective in reducing tumor volume and extending lifespan. The research also demonstrated the advantages of delivering the radionuclide therapy as two fractionated doses, as opposed to one.

South australiaPauls donnellyMatthewj harrisKevin kuanSusan jacksonPeterd roseltDavid binnsRodneyj hicksCharmainem jeffreyCarleen cullinaneJournal of nuclear medicineSir peter maccallum department of oncologyClarity pharmaceuticals ltdPeter maccallum cancer centreSchool of chemistryCentre for cancer imaging

John Violet: radiation oncologist and physician scientist who pioneered targeted radionuclide therapy for prostate cancer

John Violet: radiation oncologist and physician scientist who pioneered targeted radionuclide therapy for prostate cancer
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

Gavin yameyJohn violetPeter maccallum cancer centreஜான் வயலட்பீட்டர் மக்காலம் புற்றுநோய் மையம்